Omnicell (OMCL) to Release Quarterly Earnings on Thursday

Omnicell (NASDAQ:OMCL) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $0.57 per share and revenue of $297.88 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Omnicell Stock Down 0.4 %

OMCL stock opened at $44.69 on Thursday. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.74. The business has a 50 day moving average of $44.62 and a 200-day moving average of $42.62. The firm has a market cap of $2.07 billion, a PE ratio of -114.59, a P/E/G ratio of 29.73 and a beta of 0.78.

Insider Buying and Selling

In other news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.64% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on OMCL shares. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Barclays lifted their price objective on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Craig Hallum upped their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. upped their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Finally, Bank of America decreased their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Omnicell currently has an average rating of “Hold” and a consensus target price of $50.00.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.